I Mapped Every Sourcing Tool in Healthcare M&A. They All Miss the Same Thing.

There's a number I keep hearing in conversations with deal teams that I can't get out of my head.

Two to three weeks.

That's how long it takes most healthcare M&A teams to go from a raw data pull to a cleaned, enriched, prioritized target list that's actually ready for outreach. Not because the team is slow. Because the tools they're paying six figures a year for don't finish the job.

I've spent the last few weeks talking to fund origination leads, sell-side bankers, and platform corp dev teams about what they're actually using to source deals. Every single one of them has a stack. Most are spending $50K to $200K a year across three to five platforms - real line items on real P&Ls, renewed annually without anyone asking whether the output justifies the cost. And all of them have the same complaint: the data gets them to a universe, not a map.

If you're in healthcare M&A origination right now, you probably have some combination of these:

PitchBook ($12-40K/year depending on seat count) - The default. Good for transaction comps, fund activity, and identifying who's been acquired. Weak on independent practices that haven't transacted. One origination lead I spoke with recently said it plainly: "PitchBook has no value for what we're trying to do." That's a $40K line item.

Capital IQ ($12-30K/year) - Strong financial data on larger entities. Falls off completely below $10M revenue. Most independent physician practices don't show up at all.

ZoomInfo ($15-60K/year) - Contact data and firmographics. Useful for getting a name and phone number. Does not tell you whether a 4-physician orthopedic group in Tampa is independent, MSO-affiliated, or already under LOI with someone else.

Definitive Healthcare ($25-100K/year) - The closest thing to a healthcare-specific data platform. Claims and referral data, physician affiliations, facility profiles. Good for understanding market share. Does not tell you whether the physician owner is 63 years old with no succession plan and a lease expiring in 18 months.

Grata (formerly SourceScrub, now under Datasite) ($15-25K/year estimated) - Private company search with web-scraped enrichment. Better than PitchBook for finding companies that haven't transacted yet. Still gives you a list of names, not a diligence-ready profile. One fund I spoke with uses Grata alongside Apify for web scraping and Claude for manual categorization - three tools bolted together to do what none of them do alone.

There are newer entrants too. Rubi.ai is trying to use AI to match buyers with deals. Cyndx offers AI-powered deal sourcing at mid-five-figure annual contracts. Inven runs around $10K/year for AI-assisted target identification. Axial operates as a deal marketplace, charging per-deal fees.

Every one of these tools solves a piece of the problem. None of them solve the whole thing.

 The Gap

Here's what none of these platforms deliver:

Provider-level intelligence. How many physicians are at the practice? Are they all revenue-generating, or are two of them semi-retired and listed on NPI but seeing 5 patients a week? What's the service mix - is it all evaluation and management, or do they run infusion, imaging, procedures? These distinctions are the difference between a $2M revenue practice and an $8M revenue practice, and no subscription database will tell you.

Transaction readiness signals. Is the founder approaching retirement age? Did a junior partner just leave? Is the lease coming up for renewal? Are they in a market where a competitor just got acquired, which means a platform is consolidating around them? These are the signals that separate "interesting practice" from "practice that might actually transact in the next 12-18 months." No platform tracks this. It requires triangulating across multiple data sources that most deal teams don't have time to access, let alone cross-reference.

Financial estimation from public data. You can build a defensible revenue range for most physician practices using publicly available benchmarks - specialty-specific revenue per provider, site-of-service adjustments, ancillary revenue multipliers for things like in-house pharmacy or imaging. But it requires knowing which benchmarks to use, when to adjust, and how to present ranges that an IC committee will take seriously. The platforms give you revenue data for companies that self-report. Independent practices don't self-report.

Prioritization. This is the one that costs deal teams the most time. You pulled 200 names from a combination of PitchBook, Definitive, and your own network. Which 20 should your team spend time on this month? Not the largest - the most likely to transact, the best strategic fit for your platform thesis, the ones where outreach timing matters. That prioritization layer requires judgment layered on top of data, and it's the part that takes your VP of Corp Dev 40 hours per market.

Let me walk through exactly what I'm seeing in the sourcing workflows of the teams I've spoken with recently.